ViroMed Co.

Seoul, South Korea

ViroMed Co.

Seoul, South Korea
SEARCH FILTERS
Time filter
Source Type

The present invention relates to a pharmaceutical composition for preventing or treating peripheral vascular disease, the composition comprising, as an active ingredient: (a) hepatocyte growth factor (HGF) or an isoform thereof, and stromal cell derived factor 1 (SDF-1); or (b) a polynucleotide encoding the HGF and a polynucleotide encoding the SDF-1. The peripheral vascular disease (for example, ischemic limb disease) can be more effectively prevented or treated through the significant promotion of vascular endothelial cell migration and angiogenesis in the case of singly using the composition of the present invention than in the case of using HGF, an isoform thereof, SDF-1 or a polynucleotide codes a protein thereof.


The present invention relates to a composition for preventing or treating neurological diseases including an extract of Euphoria longan fruit, red sage and Gastrodia elata as an active ingredient. The composition of the present disclosure has a superior effect of inhibiting the activity of acetylcholinesterase (AChE), which hydrolyzes the neurotransmitter acetylcholine directly involved in impairment of cognitive function. In addition, the composition of the present disclosure is safe for the human body since the biologically safe extract of Euphoria longan fruit, red sage and Gastrodia elata is used as the active ingredient.


The present invention relates to a pharmaceutical composition for cartilage regeneration, pain suppression, and edema suppression, and more particularly, to a drug composition, comprising herbal extracts of Chaenomelis Fructus, Achyranthis Radix, Acanthopanax, Cinnamomi Cortex, Gentianae Radix, Clematidis Radix, Angelicae Radix, Cnidii Rhizoma, Gastrodiae Rhizoma, Safflower, Rhlomidis Radix, and Ledebouriellae Radix as active ingredients, which has no significant adverse side effects, suppresses pain and edema, and is effective in cartilage regeneration, thus is applicable in medicines, health foods, food additive or feed additives.


Patent
Viromed Co. | Date: 2012-03-27

The present invention relates to a pharmaceutical composition for the prevention or treatment of diabetic neuropathy, wherein the pharmaceutical composition comprises, as active ingredients, different types of isoforms of HGF or a polynucleotide encoding the isoforms. The present invention is the first invention demonstrating that diabetic neuropathy can be prevented and treated using different types of isoforms of HGF. According to the present invention, it is possible to very effectively treat diabetic neuropathy.


The present invention relates to a composition for preventing or treating amyotrophic lateral sclerosis, the composition containing, as an active ingredient, two or more isoforms of a hepatocyte growth factor (HGF) or a polynucleotide encoding the isoforms. The composition of the present invention is used to effectively prevent or treat amyotrophic lateral sclerosis.


Patent
ViroMed Co. | Date: 2010-02-12

The present invention relates to human Her-2/neu expressing plasmid constructs having anti-cancer activity and a DNA vaccine comprising same for preventing and/or treating cancer. The Her-2/neu DNA vaccines of the present invention can be effectively used as a therapeutic vaccine in reducing metastasis after tumor surgery or as a prophylactic vaccine for people with genetic high risk.


Patent
Viromed Co. | Date: 2012-11-22

The present invention relates to a cell line in which an expression construct is introduced into a genomic DNA, the expression construct including: (a) a promoter operable in animal cells and heterologous to adenoviruses; and (b) a modified adenovirus E1 coding gene sequence of SEQ ID NO:1 operatively linked to the promoter. According to the present invention, the cell line of the present invention is a novel cell line which is less likely to produce a replication competent adenovirus (RCA). The adenovirus producing cell line of the present invention has a low possibility of producing RCA due to homologous recombination, when compared with conventional cell lines. Therefore, this makes it possible to regulate the required amount of virus during gene therapy using the adenovirus and prevent tissue damage and toxic effects caused by overproduction of the adenovirus. Also, the cell line of the present invention shows superior adenovirus producing ability, as compared with an HEK293 cell which is one of conventional adenovirus producing cell lines. Thus, it is possible to produce a time and cost-saving replication incompetent adenovirus. Therefore, the cell line of the present invention effectively produces a replication incompetent adenovirus and provides a safe and effective dose of adenovirus during gene therapy.


The present invention relates to a composition for preventing or treating amyotrophic lateral sclerosis, the composition containing, as an active ingredient, two or more isoforms of a hepatocyte growth factor (HGF) or a polynucleotide encoding the isoforms. The composition of the present invention is used to effectively prevent or treat amyotrophic lateral sclerosis.


Provided is a use of a crude extract, non-polar solvent soluble extract or purified extract of the hardy kiwifruit for the preparation of therapeutic agent for treating and preventing baldness disorder and seborrheic skin disease in human and mammal, and health care food, food additives, feed additives, cosmetic composition comprising the same. The hardy kiwifruit reduced blood DHT level, promoted the formation of hair root in mouse model experiment, and inhibited the falling out of hair and improved seborrheic skin disease of volunteers such as keratigenous skin, seborrhea etc.


Patent
Viromed Co. | Date: 2014-10-01

The present invention relates to a cell line in which an expression construct is introduced into a genomic DNA, the expression construct including: (a) a promoter operable in animal cells and heterologous to adenoviruses; and (b) a modified adenovirus E1 coding gene sequence of SEQ ID NO:1 operatively linked to the promoter. According to the present invention, the cell line of the present invention is a novel cell line which is less likely to produce a replication competent adenovirus (RCA). The adenovirus producing cell line of the present invention has a low possibility of producing RCA due to homologous recombination, when compared with conventional cell lines. Therefore, this makes it possible to regulate the required amount of virus during gene therapy using the adenovirus and prevent tissue damage and toxic effects caused by overproduction of the adenovirus. Also, the cell line of the present invention shows superior adenovirus producing ability, as compared with an HEK293 cell which is one of conventional adenovirus producing cell lines. Thus, it is possible to produce a time and cost-saving replication incompetent adenovirus. Therefore, the cell line of the present invention effectively produces a replication incompetent adenovirus and provides a safe and effective dose of adenovirus during gene therapy.

Loading ViroMed Co. collaborators
Loading ViroMed Co. collaborators